145
Participants
Start Date
August 9, 2023
Primary Completion Date
September 30, 2027
Study Completion Date
September 30, 2027
IMA402 (Phase Ia)
Intravenous infusions in escalating dose levels
IMA402 (Phase Ib)
Treatment at MTD and/or RDE (Phase Ib)
IMA402 (Phase II)
Treatment at MTD/RDE based on a manageable/favorable safety profile and initial signs of anti-tumor activity of selected ISEC (Phase II)
NOT_YET_RECRUITING
Elbe Kliniken Stade- Buxtehude Elbe Klinikum Buxtehude gGmbH, Buxtehude
RECRUITING
Johannes Wesling Klinikum Minden, Minden
NOT_YET_RECRUITING
Philipps-Universitaet Marburg, Marburg
NOT_YET_RECRUITING
Justus-Liebig-Universitaet Giessen, Giessen
RECRUITING
Universitaetsklinikum Magdeburg AöR, Magdeburg
RECRUITING
Marien Hospital Duesseldorf GmbH, Düsseldorf
RECRUITING
KEM I Evang. Kliniken Essen-Mitte gGmbH, Essen
RECRUITING
Universitaetsklinikum Essen AöR, Essen
NOT_YET_RECRUITING
Universitaet Muenster, Münster
RECRUITING
Universitaetsklinikum Bonn AöR, Bonn
RECRUITING
Universitaetsklinikum Mannheim GmbH, Mannheim
RECRUITING
Universitaetsklinikum Heidelberg AöR, Heidelberg
RECRUITING
Universitaetsklinikum Ulm AöR, Ulm
RECRUITING
Klinikum Nürnberg, Nuremberg
RECRUITING
Universitaetsklinikum Erlangen AöR, Erlangen
RECRUITING
Universitaetsklinikum Regensburg, Regensburg
RECRUITING
Universitaetsklinikum Wuerzburg AöR, Würzburg
RECRUITING
Klinikum Chemnitz gGmbH, Chemnitz
RECRUITING
Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR, Dresden
RECRUITING
University Of Leipzig, Leipzig
RECRUITING
Antoni von Leeuwenhoek- Netherlands Cancer Institute, Amsterdam
RECRUITING
Leiden Universitair Medisch Centrum, Leiden
RECRUITING
Universitair Medisch Centrum Groningen, Groningen
RECRUITING
Universitair Medisch Centrum Utrecht, Utrecht
Lead Sponsor
Immatics Biotechnologies GmbH
INDUSTRY